These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1662234)

  • 1. Clinical pharmacology and toxicity of low daily administration of oral etoposide in advanced lung cancer patients.
    Katoh O; Yamada H; Hiura K; Aoki Y; Kuroki S
    J Clin Pharmacol; 1991 Dec; 31(12):1155-60. PubMed ID: 1662234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.
    Clark PI; Slevin ML; Joel SP; Osborne RJ; Talbot DI; Johnson PW; Reznek R; Masud T; Gregory W; Wrigley PF
    J Clin Oncol; 1994 Jul; 12(7):1427-35. PubMed ID: 8021734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer.
    Clark PI; Cottier B
    Semin Oncol; 1992 Dec; 19(6 Suppl 14):36-9. PubMed ID: 1336898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A phase II study of NK171 (etoposide)].
    Kimura K; Niitani H
    Gan To Kagaku Ryoho; 1985 Oct; 12(10):2011-7. PubMed ID: 2996442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study.
    Grunberg SM; Crowley J; Hande KR; Giroux D; Munshi N; Lau DH; Schroder LE; Zangmeister MH; Balcerzak SP; Hynes HE; Gandara DR
    Cancer Chemother Pharmacol; 1999; 44(6):461-8. PubMed ID: 10550566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy with cisplatin, etoposide and gallium chloride for lung cancer: individual adaptation of doses.
    Collery P; Morel M; Desoize B; Millart H; Perdu D; Prevost A; Vallerand H; Pechery C; Choisy H; Etienne JC
    Anticancer Res; 1991; 11(4):1529-32. PubMed ID: 1660690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
    Waits TM; Johnson DH; Hainsworth JD; Hande KR; Thomas M; Greco FA
    J Clin Oncol; 1992 Feb; 10(2):292-6. PubMed ID: 1310104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A phase II study of oral VP-16 in primary lung cancer].
    Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 days.
    van der Gaast A; Vlastuin M; Kok TC; Splinter TA
    Semin Oncol; 1992 Dec; 19(6 Suppl 14):8-12. PubMed ID: 1488657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic study of high dose etoposide infusion in patients with small cell lung cancer.
    Green JA; Tarpey AW; Warenius HM
    Acta Oncol; 1988; 27(6b):819-22. PubMed ID: 2852947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination chemotherapy with oral etoposide.
    Johnson DH; Hainsworth JD; Hande KR; Greco FA
    Semin Oncol; 1992 Dec; 19(6 Suppl 14):19-24. PubMed ID: 1336896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.
    Girling DJ
    Lancet; 1996 Aug; 348(9027):563-6. PubMed ID: 8774567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide.
    Minami H; Ando Y; Sakai S; Shimokata K
    J Clin Oncol; 1995 Jan; 13(1):191-9. PubMed ID: 7799020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408.
    Fujishiro M; Shinkai T; Fukuda M; Tamura T; Ohe Y; Kunitoh H; Nishiwaki Y; Sekine I; Fukuda H; Saijo N
    Jpn J Clin Oncol; 2000 Nov; 30(11):487-93. PubMed ID: 11155918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged administration of low-daily-dose etoposide: a superior dosing schedule?
    Greco FA; Hainsworth JD
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S101-4. PubMed ID: 8070017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic oral etoposide in the treatment of lung cancer.
    DeVore R; Hainsworth J; Greco FA; Hande K; Johnson D
    Semin Oncol; 1992 Dec; 19(6 Suppl 14):28-35. PubMed ID: 1336897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.